A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP

Recruiting now · Phase 3

Conditions studied: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia

In brief

This study is to evaluate the efficacy and safety of Meropenem and Pralurbactam for Injection in Subjects with HABP/VABP. The primary objective is to demonstrate non-inferiority of Meropenem and Pralurbactam to Ceftazidime and Avibactam Sodium for Injection. This study is a randomized, double-blind, active-controlled study. The total duration of the study will be approximately 32 days including screening and follow-up.

Key facts

Study ID
NCT07327619
Run by
Qilu Pharmaceutical Co., Ltd.
People needed
420
Starts
2026-01-22
Expected to finish
2028-10-01
Last updated by the study team
2026-02-17

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.